Novo Nordisk A/S
Contact: Mads Ovlisen - President & CEO
Web: http://www.novonordisk.com
E-Mail:
Address: Novo Alle, Bagsvaerd 2880, Denmark
Phone: +45-(4449)-8888 | Fax: +45-(4449)-0555 | Map/Directions >>
Profile: Novo Nordisk A/S is a healthcare company specializing in hemophilia care, growth hormone therapy, and hormone replacement therapy products. We have designed a next generation pre-filled insulin pen. It has a number of new features designed to provide improved safety, convenience and ease of use for patients & healthcare professionals. It has full-colored cartridges, labels and packaging designed to aid easier insulin type identification for patients & healthcare professionals. It provides superior dose accuracy in comparison to other injection systems, such as vials and syringe.
The company has revenues of USD 100-500 Million, has ~9000 employees.
FDA Registration Number: 9681821
US Agent: Johnsignorin / Novo Nordisk Inc.
Phone: +1-(609)-987-5967 Fax: +1-(609)-987-3916 E-Mail:
3 Products/Services (Click for related suppliers)
|
| • Erythrocytic and Leukocytic Cell Enzymes (FDA Code: JBE / 864.7100) Red blood cell enzyme assay is a device used to measure the activity in red blood cells of clinically important enzymatic reactions and their products, such as pyruvate kinase or 2,3-diphosphoglycerate. A red blood cell enzyme assay is used to determine the enzyme defects responsible for a patient's hereditary hemolytic anemia. |
| • Insulin Injector |
| • Insulin Pens |
